<?xml version="1.0" encoding="UTF-8"?>
<p>In addition to the studies reported above, small patient series (reviewed in [
 <xref rid="B29-pathogens-08-00176" ref-type="bibr">29</xref>]) and some case reports have been published. At our knowledge, at least 11 patients with HCV-associated glomerular disease experienced clinical benefit after completing therapy with DAAs [
 <xref rid="B29-pathogens-08-00176" ref-type="bibr">29</xref>,
 <xref rid="B30-pathogens-08-00176" ref-type="bibr">30</xref>,
 <xref rid="B31-pathogens-08-00176" ref-type="bibr">31</xref>,
 <xref rid="B32-pathogens-08-00176" ref-type="bibr">32</xref>,
 <xref rid="B33-pathogens-08-00176" ref-type="bibr">33</xref>,
 <xref rid="B34-pathogens-08-00176" ref-type="bibr">34</xref>].
</p>
